



LKT Laboratories, Inc.

LBH-589

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: getinfo@lktlabs.com

Web: lktlabs.com

Product Information

Product ID L0528

CAS No. 404950-80-7

Chemical Name

Synonym LBH589, Panobinostat

Formula $C_{21}H_{23}N_3O_2$

Formula Wt. 349.43

Melting Point


Purity $\geq 98\%$

Solubility DMSO 69 mg/mL (197.46 mM)
Water Insoluble
Ethanol Insoluble

Store Temp -20°C

Ship Temp Ambient

Description LBH-589 (Panobinostat) is a hydroxamic acid inhibitor of class I (1, 2, 3, and 11) histone deacetylases (HDACs) that is clinically used to treat multiple myeloma and is currently in clinical trials as a potential treatment for other cancers. This compound displays anticancer chemotherapeutic and anti-metastatic activities. LBH-589 reverses the epithelial-to-mesenchymal transition (EMT), inhibits cell proliferation, invasion, and migration, and decreases tumor growth in animal models of breast cancer. In hepatocellular carcinoma cells, LBH-589 inhibits oncogenic miRNA expression and upregulates expression of APAF1 and Beclin-1.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
L0528	5 mg	\$73.50
L0528	25 mg	\$157.50
L0528	50 mg	\$231.00

References Andreu-Vieyra CV, Berenson JR. The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma. *Ther Adv Hematol*. 2014 Dec;5(6):197-210. PMID: 25469210.

Rhodes LV, Tate CR, Segar HC, et al. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators. *Breast Cancer Res Treat*. 2014 Jun;145(3):593-604. PMID: 24810497.

Henrici A, Montalbano R, Neureiter D, et al. The pan-deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines. *Mol Carcinog*. 2013 Dec 23. [Epub ahead of print]. PMID: 24375802.

Ovejero-Sanchez M, Gonzalez-Sarmiento R, Herrero AB. Synergistic effect of chloriquine and panobinostat in ovarian cancer through induction of DNA damage and inhibition of DNA repair. *Neoplasia*. 2021 May;23(5):515-528. PMID: 339930758.

Wilson A, Gupta V, Liu Q, et al. Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer. *Neoplasia*. 2022 Feb;24(2):63-75. PMID: 34933276.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.